Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

495 ARTÍCULOS , VIENDO DEL 211 AL 225

Deep Brain Stimulation: A Paradigm Shifting Approach to Treat Parkinson's Disease

Hickey P, Stacy M.

Front Neurosci. 2016 Apr 28;10:173. doi: 10.3389/fnins.2016.00173. eCollection 2016.

Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: Two randomized phase 2 studies

Trenkwalder C, Stocchi F, Poewe W, Dronamraju N, Kenney C, Shah A, von Raison F, Graf A.

Mov Disord. 2016 Jul;31(7):1054-8. doi: 10.1002/mds.26585. Epub 2016 May 23.

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease

Tison F, Keywood C, Wakefield M, Durif F, Corvol JC, Eggert K, Lew M, Isaacson S, Bezard E, Poli SM, Goetz CG, Trenkwalder C, Rascol O.

Mov Disord. 2016 Sep;31(9):1373-80. doi: 10.1002/mds.26659. Epub 2016 May 23.

A review of disease progression models of Parkinson's disease and applications in clinical trials

Venuto CS, Potter NB, Dorsey ER, Kieburtz K.

Mov Disord. 2016 Jul;31(7):947-956. doi: 10.1002/mds.26644. Epub 2016 May 26.

Movement Disorders: A Brief Guide in Medication Management

Julius A, Longfellow K.

Med Clin North Am. 2016 Jul;100(4):733-61. doi: 10.1016/j.mcna.2016.03.002. Epub 2016 Apr 19.

The essential tremor syndromes

Elble RJ.

Curr Opin Neurol. 2016 Aug;29(4):507-12. doi: 10.1097/WCO.0000000000000347.

The nonmotor features of Parkinson's disease: pathophysiology and management advances

Reichmann H, Brandt MD, Klingelhoefer L.

Curr Opin Neurol. 2016 Aug;29(4):467-73. doi: 10.1097/WCO.0000000000000348.

Association of leptin with orthostatic blood pressure changes in Parkinson's disease

Nakamura T, Suzuki M, Okada A, Suzuki J, Hasegawa S, Koike H, Hirayama M, Katsuno M, Sobue G.

Mov Disord. 2016 Sep;31(9):1417-21. doi: 10.1002/mds.26678. Epub 2016 Jun 6.

Transducer-based evaluation of tremor

Haubenberger D, Abbruzzese G, Bain PG, Bajaj N, Benito-León J, Bhatia KP, Deuschl G, Forjaz MJ, Hallett M, Louis ED, Lyons KE, Mestre TA, Raethjen J, Stamelou M, Tan EK, Testa CM, Elble RJ.

Mov Disord. 2016 Sep;31(9):1327-36. doi: 10.1002/mds.26671. Epub 2016 Jun 6.

A clinical view on the development of technology-based tools in managing Parkinson's disease

Maetzler W, Klucken J, Horne M.

Mov Disord. 2016 Sep;31(9):1263-71. doi: 10.1002/mds.26673. Epub 2016 Jun 7.

Prodromal Parkinson's disease as defined per MDS research criteria in the general elderly community

Mahlknecht P, Gasperi A, Willeit P, Kiechl S, Stockner H, Willeit J, Rungger G, Sawires M, Nocker M, Rastner V, Mair KJ, Hotter A, Poewe W, Seppi K.

Mov Disord. 2016 Sep;31(9):1405-8. doi: 10.1002/mds.26674. Epub 2016 Jun 6.

Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia

Abdelnour C, van Steenoven I, Londos E, Blanc F, Auestad B, Kramberger MG, Zetterberg H, Mollenhauer B, Boada M, Aarsland D; European DLB Consortium.

Mov Disord. 2016 Aug;31(8):1203-8. doi: 10.1002/mds.26668. Epub 2016 Jun 14.

Apoptosis-inducing factor in nigral dopamine neurons: Higher levels in primates than in mice

Peneder TM, Bauer J, Pifl C.

Mov Disord. 2016 Nov;31(11):1729-1733. doi: 10.1002/mds.26695. Epub 2016 Jun 14.

Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale

Hewer S, Varley S, Boxer AL, Paul E, Williams DR; AL-108-231 Investigators.

Mov Disord. 2016 Oct;31(10):1574-1577. doi: 10.1002/mds.26694.

Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease

Malek N, Lawton MA, Swallow DM, Grosset KA, Marrinan SL, Bajaj N, Barker RA, Burn DJ, Hardy J, Morris HR, Williams NM, Wood N, Ben-Shlomo Y, Grosset DG; PRoBaND Clinical Consortium.

Mov Disord. 2016 Oct;31(10):1518-1526. doi: 10.1002/mds.26698.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias